Arrowhead Pharmaceuticals: From Gene Whisperer to Pharma Rising Star – The Bet on RNAi Growth
Reading Time: 3 minutes
Arrowhead has a leading technology in the field of RNA interference (RNAi) with its proprietary TRiM™ platform, successfully validated through strategic partnerships with Big Pharma and the first FDA approval (Plozasiran). The company is making the critical leap from a pure R&D entity to a commercial player, with future revenues increasingly coming from direct product sales rather than solely from milestone payments. The extensively diversified pipeline, especially in the cardiovascular and CNS areas, offers tremendous growth potential....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
